Research programme: chelating agents - PALUMEDAlternative Names: PA 1637
Latest Information Update: 04 Feb 2011
At a glance
- Originator PALUMED
- Mechanism of Action Chelating agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 04 Feb 2011 Preclinical development is ongoing in France
- 26 Feb 2007 Preclinical trials in Alzheimer's disease in France (unspecified route)